Johnson & Johnson (JNJ)vsUtah Medical Products Inc (UTMD)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
UTMD
Utah Medical Products Inc
$68.84
-5.78%
HEALTHCARE · Cap: $231.97M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 284381% more annual revenue ($99.33B vs $34.92M). UTMD leads profitability with a 30.5% profit margin vs 16.2%. JNJ appears more attractively valued with a PEG of 2.82. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
UTMD
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Margin of Safety
-49.3%
Fair Value
$42.70
Current Price
$68.84
$26.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 34.8%
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Revenue declined 12.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : UTMD
The strongest argument for UTMD centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.5% and operating margin at 34.8%.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : UTMD
The primary concerns for UTMD are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while UTMD is a declining play — different risk/reward profiles.
UTMD carries more volatility with a beta of 0.39 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 54/100), backed by strong 16.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Utah Medical Products Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The company is headquartered in Midvale, Utah.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?